Erich Schlick
Director/Board Member at SYMETIS SA
Profile
Erich Schlick is the founder of BASF Pharma Ltd.
He currently holds multiple positions, including Chairman at Evolva SA, Chairman at Sensimed SA, Independent Chairman at NBE-Therapeutics AG, Director at Immatics Biotechnologies GmbH, Director & Professor at Ruprecht-Karls-Universität Heidelberg, Director at Symetis SA, Director at Zentralinstitut für Seelische Gesundheit, Director at Immatics US, Inc., and General Partner at Wellington Partners GmbH.
In the past, he has worked as a Director at SuperSonic Imagine SA, Director at Elara Pharmaceuticals GmbH, Director at Evolva Holding SA, Member-Supervisory Board at Trigen Holdings AG, and Member-Supervisory Board at ImevaX.
GmbH.
Dr. Schlick obtained a doctorate degree from Ruprecht-Karls-Universität Heidelberg.
Erich Schlick active positions
Companies | Position | Start |
---|---|---|
SYMETIS SA | Director/Board Member | - |
Wellington Partners GmbH
Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | Private Equity Investor | 30/09/2005 |
Sensimed SA
Sensimed SA Medical SpecialtiesHealth Technology Sensimed SA develops non-invasive soft contact lens-based solutions. It offers solutions to monitor fluctuations in intraocular pressure continuously. The company was founded by Matteo Leonardi and Sacha Cerboni in 2003 and is headquartered in Lausanne, Switzerland. | Chairman | - |
Evolva SA
Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Chairman | 17/11/2009 |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Director/Board Member | 18/11/2009 |
Zentralinstitut für Seelische Gesundheit | Director/Board Member | 14/12/2009 |
BASF Pharma Ltd.
BASF Pharma Ltd. Pharmaceuticals: MajorHealth Technology Part of Abbott Laboratories, BASF Pharma Ltd. is a British company that produces excipients and active ingredients. The private company is based in Kent, UK. The company was founded by Erich Schlick. BASF Pharma was acquired by Abbott Laboratories from BASF SE on March 02, 2001 for $6,128.79 million. | Founder | 14/12/2009 |
Ruprecht-Karls-Universität Heidelberg | Director/Board Member | 14/12/2009 |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Director/Board Member | - |
░░░░░░░░░░░░░░░░ ░░ | ░░░░░░░░ | ░░░░░░░░░░ |
Former positions of Erich Schlick
Companies | Position | End |
---|---|---|
░░░░░░ ░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
░░░░░ ░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░ | ░░░░░░░░░░ |
Training of Erich Schlick
Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
EVOLVA HOLDING SA | Consumer Non-Durables |
Private companies | 13 |
---|---|
Wellington Partners GmbH
Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | Finance |
BASF Pharma Ltd.
BASF Pharma Ltd. Pharmaceuticals: MajorHealth Technology Part of Abbott Laboratories, BASF Pharma Ltd. is a British company that produces excipients and active ingredients. The private company is based in Kent, UK. The company was founded by Erich Schlick. BASF Pharma was acquired by Abbott Laboratories from BASF SE on March 02, 2001 for $6,128.79 million. | Health Technology |
Trigen Holdings AG
Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | Commercial Services |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
Symetis SA
Symetis SA BiotechnologyHealth Technology Symetis SA develops minimally invasive heart valve replacement devices. Its products include ACURATE TA and ACURATE neo. The company was founded by Simon P. Hoerstrup and Gregor Zünd on September 5, 2001 and is headquartered in Ecublens, Switzerland. | Health Technology |
SuperSonic Imagine SA
SuperSonic Imagine SA Medical SpecialtiesHealth Technology SuperSonic Imagine SA specializes in ultrasound medical imaging. The company designs, develops and markets a new generation ultrasound system, Aixplorer with an UltraFastTM platform that can acquire images faster than conventional ultrasound systems. Its products are used for general imaging, vascular, hepatology, gastroenterology, and research procedures. It operates under the Aixplorer trademark. SuperSonic Imagine was founded by Jacques Souquet, Armen Sarvazyan, Claude Cohen-Bacrie, Damien Dolimier, Georges Charpak, Jérémy Bercoff, Mickaël Tanter, Mathias Fink and Marianne Leven on March 10, 2005 and is headquartered in Aix-en-Provence, France. | Health Technology |
Evolva SA
Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Commercial Services |
Sensimed SA
Sensimed SA Medical SpecialtiesHealth Technology Sensimed SA develops non-invasive soft contact lens-based solutions. It offers solutions to monitor fluctuations in intraocular pressure continuously. The company was founded by Matteo Leonardi and Sacha Cerboni in 2003 and is headquartered in Lausanne, Switzerland. | Health Technology |
Zentralinstitut für Seelische Gesundheit | |
NBE-Therapeutics AG
NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | Health Technology |
ImevaX GmbH
ImevaX GmbH BiotechnologyHealth Technology ImevaX GmbH develops vaccines against pathogens of chronic infectious diseases, especially helicobacter pylori. It offers diagnostic and therapeutic methods for bacterial agents. The company was founded by Markus Gerhard in 2014 and is headquartered in Munich, Germany. | Health Technology |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Health Technology |
Elara Pharmaceuticals GmbH
Elara Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Elara Pharmaceuticals GmbH focuses on the development of novel treatments for malignant diseases. It has developed three distinct and proprietary dual mechanism chemotypes that potently inhibit the HIF signaling pathway and induce apoptosis. The firm has identified compounds with excellent in vitro activity against a diverse set of tumor cell lines and superior pharmacokinetic and toxicity profiles in vivo. The company was founded by Frank Gannon, Joe D. Lewis and George Reid on July 27, 2006 and is headquartered in Heidelberg, Germany. | Health Technology |
- Stock Market
- Insiders
- Erich Schlick